AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...
New study reveals crucial differences in gene activity and opens up personalized therapeutic approaches Krems (Austria), 15.
KL Krems & MedUni Vienna study provides new insights into the genetic mechanisms of birch pollen allergy: Krems, Austria Friday, January 17, 2025, 16:00 Hrs [IST] An innovative st ...